Corcept Therapeutics (CORT) is trading higher as investors react to updated ALS pipeline data that extends beyond the initial DAZALS readout. The company reported two-year overall survival results from its Phase 2 DAZALS trial of dazucorilant, emphasizing a large reduction in mortality risk versus placebo in specified comparisons and framing the dataset as supportive of rapid advancement into a pivotal program. (ir.corcept.com)

DAZALS was a randomized, double-blind, placebo-controlled Phase 2 study in ALS; while it did not meet its primary functional endpoint (ALSFRS-R), Corcept highlighted that overall survival was a secondary endpoint and described continued survival separation in follow-up analyses. The company said patients receiving 300 mg dazucorilant showed an 87% reduction in risk of death versus a placebo group that did not switch to 300 mg in the extension, and it reiterated that gastrointestinal tolerability is being addressed via dose-titration work. (ir.corcept.com)

Corcept said it expects to initiate a pivotal Phase 3 study of dazucorilant in ALS later in 2026, which investors are treating as the next gating event for the program. Separately, the company recently reported Q1 2026 results and increased 2026 revenue guidance to $950 million–$1.05 billion, while describing early launch dynamics for its newly approved ovarian-cancer product Lifyorli, adding another narrative tailwind alongside pipeline progress. (ir.corcept.com)

Despite the upbeat survival headline, Corcept itself noted DAZALS missed its primary endpoint, and it is positioning follow-on work and trial design choices as critical to confirm whether the apparent mortality benefit can be replicated in a registrational setting. Investors are also tracking whether spending to launch Lifyorli and to support growth initiatives pressures near-term profitability, even as management has guided for a return to profitability in Q2 2026. (ir.corcept.com)